New Spike in COVID Infections, 1M+ Death Toll, Underscore Potential Value of Aditxt Inc.’s (NASDAQ: ADTX) Immune Monitoring Technologies

  • Biotech innovation company Aditxt, Inc. is a Richmond, VA based company focused on developing and commercializing technologies to monitor and reprogram the immune system with the ultimate goal of improving patient outcomes for a variety of conditions ranging from seasonal allergies to organ transplant rejection
  • Aditxt’s first commercial product, AditxtScore(TM), helps patients obtain data relating to COVID-19 infection and vulnerability
  • While immunization rates and the seasonal reduction of COVID infections have spurred optimism about enjoying normal public activities, a recent spike in COVID infections has led national health officials to again warn Americans to not become complacent about the pandemic
  • Health officials also recently acknowledged evidence that COVID-related deaths have now exceeded 1 million in the United States alone, making the country’s total the highest in the world

Johns Hopkins University announced in May that COVID-19-related deaths in the United States had surpassed 1 million just over two years after the outbreak of the worldwide pandemic, the highest recorded national death toll from COVID, while media reports acknowledged that the difficulty of precisely tracking COVID infections means the 1 million mark may have been passed “days or months earlier” (https://ibn.fm/W6f7J).

While local communities nationwide have mostly seen falling COVID infections rates during the warming climate and residents have been further encouraged by vaccination campaigns to enjoy public activities…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to ADTX are available in the company’s newsroom at https://ibn.fm/ADTX

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.